Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.
What Dishman files
- Others56
- Investor Meet24
- Board Meeting17
- Important14
- Updates12
- PPTs10
Dishman Carbogen Amcis Limited (DCAL) has announced its 19th Annual General Meeting. Details on attending and voting will be shared with shareholders in due course. Important corporate governance event upcoming.
The company has announced a board meeting where the financial results for the year ending March 31, 2026, were approved. It secured CHF 200 million (~2452 Cr) in ECB from a promoter group for debt refinancing and approved increasing borrowing limits to Rs. 4,000 Cr. Goodwill amortization life was revised...
Dishman Carbogen Amcis (DCAL) has scheduled its 18th Annual General Meeting (AGM) for September 29, 2025. Shareholders can attend virtually via Video Conferencing/OAVM, with further attendance details to follow.
Dishman Carbogen Amcis' Naroda unit secured a US FDA Establishment Inspection Report (EIR), signaling inspection closure. This confirms continued US FDA approval for its Naroda, Bavla, Switzerland, and Netherlands facilities.
The company's Board has approved a revised framework for the disclosure of unpublished price sensitive information (UPSI). This update is a proactive step to align the company's internal policies with recent changes in regulatory guidelines concerning UPSI definitions. This move strengthens corporate governance, enhances transparency, and ensures robust compliance with...